Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Vilas A Gupta

11PUBLICATIONS
62CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyMolecular targetsRegenerative medicine (incl. stem cells)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

Sort by Publication Date:
|Sep 13, 2024
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.

Nisha S Joseph, Jonathan L Kaufman, Vilas A Gupta

|Dec 19, 2023
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience.

Sara A Scott, Ellen M Marin, Kathryn T Maples

|Nov 13, 2023
Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors.

Dennis Juarez, Roberta Buono, Shannon M Matulis

|May 26, 2023
Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.

Ricardo de Matos Simoes, Ryosuke Shirasaki, Sondra L Downey-Kopyscinski

|Feb 22, 2023
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience.

Kathryn T Maples, Kevin H Hall, Nisha S Joseph

|Sep 28, 2022
Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma.

Aditi Sharma, Remya Nair, Abhinav Achreja

Pageof 2

Frequent Collaborators

7 joint publications

Craig C Hofmeister

7 joint publications

Lawrence H Boise

6 joint publications

Benjamin G Barwick

5 joint publications

Jonathan L Kaufman

4 joint publications

Ajay K Nooka

4 joint publications

Sagar Lonial

4 joint publications

Madhav V Dhodapkar

3 joint publications

Jonathan J Keats

2 joint publications

Kathryn T Maples

2 joint publications

Mala Shanmugam

Frequent Collaborators

7 joint publications

Craig C Hofmeister

7 joint publications

Lawrence H Boise

6 joint publications

Benjamin G Barwick

5 joint publications

Jonathan L Kaufman

Top Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on : Oct 27, 2014

27.4K
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on : Sep 15, 2023

616
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on : May 15, 2019

13.2K
See more related videos

Top Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on : Oct 27, 2014

27.4K
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on : Sep 15, 2023

616
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on : May 15, 2019

13.2K
See more related videos